Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Pre-validation data generated during the program demonstrated strong analytical performance, including high sensitivity for impurity detection at low thresholds, excellent linearity across the tested range, and consistent chromatographic behavior suitable for routine analytical application

  60% confidence

• Establishing reliable and sensitive analytical methods is critical to supporting reproducible manufacturing and advancing our program toward IND-enabling studies and clinical development

  60% confidence

• The method will form the basis for formal analytical test procedures as part of the Company's broader chemistry, manufacturing, and controls (CMC) program

  60% confidence

• Completion of this analytical method development program represents an important step forward in strengthening the quality and control framework for our polymer platform

  60% confidence

Cited in these Via News reports

• Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →